Washington Capital Management Inc. Raises Stake in Hologic, Inc. (NASDAQ:HOLX)

Washington Capital Management Inc. boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 94.8% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 15,445 shares of the medical equipment provider's stock after acquiring an additional 7,515 shares during the quarter. Hologic comprises about 0.8% of Washington Capital Management Inc.'s portfolio, making the stock its 29th largest position. Washington Capital Management Inc.'s holdings in Hologic were worth $954,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Norges Bank acquired a new position in Hologic in the 4th quarter worth approximately $133,414,000. Boston Partners lifted its stake in Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after acquiring an additional 1,602,463 shares during the period. Champlain Investment Partners LLC purchased a new stake in shares of Hologic in the 4th quarter valued at $79,291,000. Northern Trust Corp increased its stake in shares of Hologic by 26.9% in the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock worth $226,898,000 after acquiring an additional 668,086 shares during the period. Finally, Invesco Ltd. raised its holdings in shares of Hologic by 16.4% during the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock worth $293,434,000 after purchasing an additional 572,187 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Insider Transactions at Hologic

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The stock was purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the purchase, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.88% of the company's stock.

Analysts Set New Price Targets

HOLX has been the topic of several recent research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Morgan Stanley dropped their target price on Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Citigroup reduced their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Evercore ISI lowered their price objective on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research report on Friday, May 2nd. Finally, Wall Street Zen lowered shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Twelve analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $77.42.

Hologic Trading Down 0.9%

Shares of Hologic stock traded down $0.56 on Wednesday, reaching $64.58. The company had a trading volume of 2,720,286 shares, compared to its average volume of 2,304,520. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The firm's 50 day moving average price is $58.42 and its two-hundred day moving average price is $65.16. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The firm has a market cap of $14.39 billion, a PE ratio of 20.37, a PEG ratio of 2.14 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the firm earned $1.03 EPS. The firm's revenue for the quarter was down 1.2% on a year-over-year basis. Sell-side analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.